Income Statement (Annual)
ATRS / Antares Pharma, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000 except per share units.
|Revenue From Contract With Customer Excluding Assessed Tax||-||-||-||-||-||-||-||-||-|
|Cost Of Revenue|
|Cost Of Goods And Services Sold||-||-||-||-||-||-||-||-||-|
|Research And Development Expense||7,902||8,803||6,699||14,922||15,263||18,638||19,731||21,127||13,147|
|Selling General And Administrative Expense||-||-||-||9,585||17,008||31,740||26,931||26,395||30,353|
|Operating Income Loss||-9,694||-6,026||-4,437||-11,452||-20,850||-35,113||-20,462||-24,117||-16,451|
|Other Nonoperating Income Expense||-||-65||49||24||-59||-90||-22||-122||271|
|Net Income Loss||-10,291||-6,091||-4,388||-11,427||-20,507||-35,152||-20,659||-24,339||-16,743|
|Earnings Per Share Basic And Diluted||-||-||-0||-0||-0||-0||-0||-0||-0|
|Weighted Average Number Of Share Outstanding Basic And Diluted||-||-||96,995||110,185||126,897||130,550||146,594||154,992||156,054|
Peers - Surgical and Medical Instruments and Apparatus (3841)
AMDA / Amedica Corporation
CASM / CAS Medical Systems, Inc.
CYTX / Cytori Therapeutics, Inc.
DRIO / DarioHealth Corp
DSCI / Derma Sciences, Inc.
GID / GI DYNAMICS, INC.
HART / Harvard Apparatus Regenerative Technology, Inc.
ICAD / icad, inc.
MDXG / MiMedx Group, Inc.
Related News Stories
(Reuters) - The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc’s drug to treat low testosterone levels in men, the company said, nearly a year after rejecting the injection.
The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August. Let’s take a look. (0-6)
Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 drugs in the full year. (14-3)
Despite deciding earlier in 2018 to hold onto our investment in Myriad Genetics, my investment club opted to divest a portion in July.
Management strategy of pursuing a combination of proprietary and partnered drugs is derisking future growth while providing enhanced upside with proprietary offerings. (23-2)
as of ET